DLL3 is an inhibitory Notch ligand that is highly expressed in SCLC and other neuroendocrine tumors but minimally expressed in healthy tissues, which is why it has been explored as a potential therapeutic target in SCLC [48]. This evidence concerns the gene DLL3 and small cell lung carcinoma.